Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Shenzhen Lachesis Mhealth Raises $21 Million in B+ Round

publication date: Feb 4, 2020

Shenzhen Lachesis Mhealth raised $21 million in a Series B+ round to support its patient care medical device offerings for hospitals. In 2018, Lachesis completed a $29 million Series B financing. The company's Intelligent Hospital Ward System includes a diagnosis and treatment assistant, wireless monitoring and other services to improve patient care. Lachesis says its product targets the post-acute-care market in general hospitals. Shenzhen Capital Group and ShenZhen GTJA Investment Group both participated in the B+ round; GTJA led the earlier B round. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital